Lumos Diagnostics Holdings Ltd
Company Profile
Business description
Lumos Diagnostics Holdings Ltd is engaged in selling Products and providing Services to customers. Its product offering includes rapid, point-of-care diagnostic test products, mainly focused on the diagnosis and management of infectious diseases. Its product is FebriDx, a point-of-care test for detecting and differentiating viral and bacterial respiratory infections. Its Service offering includes contract research and development services specialising in innovation, development, manufacturing and commercialisation of point-of-care diagnostic test solutions. The Company has one operating segment, being the provision of point-of-care diagnostics goods and services. It operates in the United States and Australia, with the majority of revenue generated from the United States.
Contact
2724 Loker Avenue West
CarlsbadCA92010
USAT: +1 855 586-6739
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
stocks
Our view after REA’s share price rally
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.40 | 18.70 | 0.20% |
| CAC 40 | 8,151.86 | 12.86 | 0.16% |
| DAX 40 | 25,953.05 | 132.69 | 0.51% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,724.48 | 50.54 | 0.47% |
| HKSE | 24,448.95 | 32.91 | -0.13% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 58,775.50 | 1,340.73 | 2.33% |
| NZX 50 Index | 13,973.62 | 24.88 | -0.18% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,029.70 | 8.90 | 0.10% |
| SSE Composite Index | 3,660.79 | 11.61 | 0.32% |